{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Neoplasms&page=12", "query": { "condition": "Neck Neoplasms", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 4129, "total_pages": 413, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Neoplasms&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Neoplasms&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T05:04:02.147Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04344795", "title": "Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Endometrial Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma", "Solid Tumors With PIK3Ca Mutation" ], "interventions": [ { "name": "TPST-1495 twice daily", "type": "DRUG" }, { "name": "TPST-1495 once daily or on intermittent schedule", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempest Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2020-05-06", "completion_date": "2024-09-25", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 11, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04344795" }, { "nct_id": "NCT00470184", "title": "Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470184" }, { "nct_id": "NCT00006799", "title": "Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anorexia", "Cachexia", "Head and Neck Cancer", "Quality of Life" ], "interventions": [ { "name": "megestrol acetate", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "2000-10-01", "completion_date": "2002-09-06", "has_results": false, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006799" }, { "nct_id": "NCT04359199", "title": "QUantitative Assessment of Swallowing After Radiation (QUASAR)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer", "Dysphagia", "Oropharyngeal Dysphagia", "Oropharynx Cancer", "Oropharynx Squamous Cell Carcinoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Immunotherapy", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Loren Mell, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-09-01", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 2, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04359199" }, { "nct_id": "NCT02062632", "title": "Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Carcinoma", "Hypopharyngeal Carcinoma", "Laryngeal Carcinoma", "Lymphoma", "Mesothelioma", "Metastatic Malignant Neoplasm in the Lung", "Metastatic Malignant Neoplasm in the Pleura", "Metastatic Malignant Neoplasm in the Spinal Cord", "Non-Small Cell Lung Carcinoma", "Sarcoma", "Small Cell Lung Carcinoma", "Thymic Carcinoma", "Thymoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Doxepin Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-04-14", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2019-10-01", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Green Bay", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02062632" }, { "nct_id": "NCT00088907", "title": "Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Head and Neck Cancer", "Metastatic Head and Neck Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2004-08", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-05-06", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088907" }, { "nct_id": "NCT07460765", "title": "Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hnscc", "Head and Neck", "Squamous Cell Cancer", "Squamous Carcinoma", "Squamous Cell Cancer of Head and Neck (SCCHN)", "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)", "Squamous Cell Carcinoma Mouth", "Squamous Carcinoma Poorly Differentiated", "Squamous Cell Cancer of the Head and Neck", "Squamous Cell Carcinoma (SCC) of the Oral Cavity", "Squamous Cell Carcinoma (SCC)" ], "interventions": [ { "name": "Nivo800", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-07-03", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07460765" }, { "nct_id": "NCT04846309", "title": "Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "FMISO PET CT", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04846309" }, { "nct_id": "NCT02649530", "title": "A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma, Head And Neck" ], "interventions": [ { "name": "WNT974", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649530" }, { "nct_id": "NCT03551028", "title": "HPV DNA Testing Through Mobile Mammography Unit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "HPV self collection", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "30 Years to 65 Years · Female only" }, "enrollment_count": 33, "start_date": "2016-07", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-11-15T05:04:02.147Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03551028" } ] }